Integrierte Koinzidenzbildgebung bei Bronchialkarzinomen

Zusammenfassung

Aufgrund des meist regelhaft erhöhten Glukosestoffwechsels eignet sich das Bronchialkarzinom und seine Metastasen gut für die Darstellung durch die Positronen-Emissions-Tomographie mit [ F-18]Fluor-Deoxy-Glukose. Es ist eine der am ehesten besten untersuchten Indikationen an dezidierten Geräten. Der Stellenwert der Koinzidenzbildgebung bei dieser Fragestellung wird anhand eigener Daten und einer Literaturübersicht beleuchtet, ein Hauptaugenmerk liegt auf den Möglichkeiten und Grenzen der Methode im Vergleich zu den Modalitäten des konventionellen Stagings.

Abstract

The high utilisation of glucose by most types of bronchial carcinoma and its metastases makes imaging with of positron emission tomography using [F-18]fluoro-deoxy-glucose feasible. Lung cancer is one of the best proved indications of this methods for dedicated scanners. The significance of the coincidence technique (hybrid PET) is highlighted by own data and a review of literature, the possibilities and limitations of the method in comparison to the modalities of the conventional staging are the main focus of the paper.

Bronchialkarzinom - Koinzidenzbildgebung - FDG - Staging

Bronchial carcinoma - coincidence imaging - FDG - staging

Literatur

• 1 Ak I, Blokland J A, Pauwels E K, Stokkel M P. The clinical value of ¹⁸F-FDG detection with a dual-head coincidence camera: a review.  Eur J Nucl Med. 2001;  28 763-778
• 2 Al-Sugair A, Coleman R E. Applications of PET in lung cancer.  Semin Nucl Med. 1998;  28 303-319
• 3 Becker N, Muscat J E, Wynder E L. Cancer mortality in the United States and Germany.  J Cancer Res Clin Oncol. 2001;  127 293-300
• 4 Boren E L, Delbeke D, Patton J A, Sandler M P. Comparison of FDG PET and positron coincidence detection imaging using a dual-head gamma camera with 5/8-inch NaI(Tl) crystals in patients with suspected body malignancies.  Eur J Nucl Med. 1999;  26 379-387
• 5 Bury T, Corhay J L, Duysinx B, Daenen F, Ghaye B, Barthelemy N, Rigo P, Bartsch P. Value of FDG-PET in detecting residual or recurrent nonsmall cell lung cancer.  Eur Respir J. 1999;  14 1376-1380
• 6 Dietlein M, Weber K, Gandjour A, Moka D, Theissen P, Lauterbach K W, Schicha H. Cost-effectiveness of FDG-PET for the management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results.  Eur J Nucl Med. 2000;  27 1598-1609
• 7 Drane W E, Abbott F D, Nicole M W, Mastin S T, Kuperus J H. Technology for FDG SPECT with a relatively inexpensive gamma camera. Work in progress.  Radiology. 1994;  191 461-465
• 8 Dresel S, Schwenzer K, Brinkbaumer K, Schmid R, Szeimies U, Popperl G, Hahn K. [[F-18]FDG imaging of head and neck tumors: comparison of hybrid PET, dedicated PET and CT].  Nuklearmedizin. 2001;  40 172-178
• 9 Erasmus J J, McAdams H P, Rossi S E, Goodman P C, Coleman R E, Patz E F. FDG PET of pleural effusions in patients with non-small cell lung cancer.  AJR Am J Roentgenol. 2000;  175 245-249
• 10 Guhlmann A, Storck M, Kotzerke J, Moog F, Sunder-Plassmann L, Reske S N. Lymph node staging in non-small cell lung cancer: evaluation by [18F]FDG positron emission tomography (PET).  Thorax. 1997;  52 438-441
• 11 Hellwig D, Ukena D, Paulsen F, Bamberg M, Kirsch C M. [Metaanalysis of the efficacy of positron emission tomography with F-18-fluorodeoxyglucose].  Pneumologie. 2001;  55 367-377
• 12 Jarritt P H, Acton P D. PET imaging using gamma camera systems: a review.  Nucl Med Commun. 1996;  17 758-766
• 13 Leonard C T, Whyte R I, Lillington G A. Primary non-small-cell lung cancer: determining the suitability of the patient and tumor for resection.  Curr Opin Pulm Med. 2000;  6 391-395
• 14 Lewellen T K, Miyaoka R S, Swan W L. PET imaging using dual-headed gamma cameras: an update.  Nucl Med Commun. 1999;  20 5-12
• 15 Lottes G, Schober O. [Costs of F-18-FDG PET with a satellite concept: update].  Nuklearmedizin. 2000;  39 72-76
• 16 Mac Manus M P, Hicks R J, Matthews J P, Hogg A, McKenzie A F, Wirth A, Ware R E, Ball D L. High rate of detection of unsuspected distant metastases by PET in apparent Stage III non-small-cell lung cancer: implications for radical radiation therapy.  Int J Radiat Oncol Biol Phys. 2001;  50 287-293
• 17 Macfarlane D J, Cotton L, Ackermann R J, Minn H, Ficaro E P, Shreve P D, Wahl R L. Triple-head SPECT with 2-[fluorine-18]fluoro-2-deoxy-D-glucose (FDG): initial evaluation in oncology and comparison with FDG PET.  Radiology. 1995;  194 425-429
• 18 Marom E M, McAdams H P, Erasmus J J, Goodman P C, Culhane D K, Coleman R E, Herndon J E, Patz EF J r. Staging non-small cell lung cancer with whole-body PET.  Radiology. 1999;  212 803-809
• 19 Martin W H, Delbeke D, Patton J A, Hendrix B, Weinfeld Z, Ohana I, Kessler R M, Sandler M P. FDG-SPECT: correlation with FDG-PET.  J Nucl Med. 1995;  36 988-995
• 20 McLoud T C, Bourgouin P M, Greenberg R W, Kosiuk J P, Templeton P A, Shepard J A, Moore E H, Wain J C, Mathisen D J, Grillo H C. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling.  Radiology. 1992;  182 319-323
• 21 Mountain C F. The international system for staging lung cancer.  Semin Surg Oncol. 2000;  18 106-115
• 22 Ohta M, Tokuda Y, Suzuki Y, Kubota M, Makuuchi H, Tajima T, Nasu S, Yasuda S, Shohtsu A. Whole body PET for the evaluation of bony metastases in patients with breast cancer: comparison with ⁹⁹Tcm-MDP bone scintigraphy.  Nucl Med Commun. 2001;  22 875-879
• 23 Park B J, Louie O, Altorki N. Staging and the surgical management of lung cancer.  Radiol Clin North Am. 2000;  38 545-561
• 24 Pieterman R M, van Putten J W, Meuzelaar J J, Mooyaart E L, Vaalburg W, Koeter G H, Fidler V, Pruim J, Groen H J. Preoperative staging of non-small-cell lung cancer with positron-emission tomography.  N Engl J Med. 2000;  343 254-261
• 25 Roman M R, Rossleigh M A, Angelides S, Walker B M, Dixon J. Staging and managing lung tumors using F-18 FDG coincidence detection.  Clin Nucl Med. 2001;  26 383-388
• 26 Sasaki M, Ichiya Y, Kuwabara Y, Akashi Y, Yoshida T, Fukumura T, Murayama S, Ishida T, Sugio K, Masuda K. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with X-ray computed tomography.  Eur J Nucl Med. 1996;  23 741-747
• 27 Schmid R A, Hautmann H, Poellinger B, Kellner W, Moisseev A, Brinkbaeumer K, Weiss M, Hahn K, Dresel S. Staging of recurrent and advanced lung cancer with 18F-FDG PET in a coincidence technique (hybrid PET).  Nucl Med Commun. 2003;  24 37-45
• 28 Schumacher T, Brink I, Mix M, Reinhardt M, Herget G, Digel W, Henke M, Moser E, Nitzsche E. FDG-PET imaging for the staging and follow-up of small cell lung cancer.  Eur J Nucl Med. 2001;  28 483-488
• 29 Scott W J, Shepherd J, Gambhir S S. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.  Ann Thorac Surg. 1998;  66 1876-1883
• 30 Shreve P D, Steventon R S, Deters E C, Kison P V, Groß M D, Wahl R L. Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose imaging: dual-head coincidence gamma camera versus positron emission tomographic scanner.  Radiology. 1998;  207 431-437
• 31 Slosman D O, Spiliopoulos A, Couson F, Nicod L, Louis O, Lemoine R, Donath A, Junod A F. Satellite PET and lung cancer: a prospective study in surgical patients.  Nucl Med Commun. 1993;  14 955-961
• 32 Som P, Atkins H L, Bandoypadhyay D, Fowler J S, MacGregor R R, Matsui K, Oster Z H, Sacker D F, Shiue C Y, Turner H, Wan C N, Wolf A P, Zabinski S V. A fluorinated glucose analog, 2-fluoro-2-deoxy-D-glucose (F-18): nontoxic tracer for rapid tumor detection.  J Nucl Med. 1980;  21 670-675
• 33 Stevens H, Bakker P F, Schlosser N J, van Rijk P P, de Klerk J M. Use of a dual-head coincidence camera and 18F-FDG for detection and nodal staging of non-small cell lung cancer: accuracy as determined by 2 independent observers.  J Nucl Med. 2003;  44(3) 336-340
• 34 Stokkel M P, Bakker P F, Heine R, Schlosser N J, Lammers J W, Van Rijk P P. Staging of lymph nodes with FDG dual-headed PET in patients with non-small-cell lung cancer.  Nucl Med Commun. 1999;  20 1001-1007
• 35 Tatsumi M, Yutani K, Watanabe Y, Miyoshi S, Tomiyama N, Johkoh T, Kusuoka H, Nakamura H, Nishimura T. Feasibility of fluorodeoxyglucose dual-head gamma camera coincidence imaging in the evaluation of lung cancer: comparison with FDG PET.  J Nucl Med. 1999;  40 566-573
• 36 Vansteenkiste J F, Stroobants S G, De Leyn P R, Dupont P J, Bogaert J, Maes A, Deneffe G J, Nackaerts K L, Verschakelen J A, Lerut T E, Mortelmans L A, Demedts M G. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients.  J Clin Oncol. 1998;  16 2142-2149
• 37 Vesselle H, Schmidt R A, Pugsley J M, Li M, Kohlmyer S G, Vallires E, Wood D E. Lung cancer proliferation correlates with [F-18]fluorodeoxyglucose uptake by positron emission tomography.  Clin Cancer Res. 2000;  6 3837-3844
• 38 Wahl R L, Hutchins G D, Buchsbaum D J, Liebert M, Grossman H B, Fisher S. ¹⁸ F-2-deoxy-2-fluoro-D-glucose uptake into human tumor xenografts. Feasibility studies for cancer imaging with positron-emission tomography.  Cancer. 1991;  67 1544-1550
• 39 Wahl R L, Quint L E, Greenough R L, Meyer C R, White R I, Orringer M B. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation.  Radiology. 1994;  191 371-377
• 40 Weber W, Young C, Abdel-Dayem H M, Sfakianakis G, Weir G J, Swaney C M, Gates M, Stokkel M P, Parker A, Hines H, Khanvali B, Liebig J R, Leung A N, Sollitto R, Caputo G, Wagner H N, Jr. Assessment of pulmonary lesions with ¹⁸F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras.  J Nucl Med. 1999;  40 574-578
• 41 Weber W A, Neverve J, Sklarek J, Ziegler S I, Bartenstein P, King B, Treumann T, Enterrottacher A, Krapf M, Haussinger K E, Lichte H, Prauer H W, Thetter O, Schwaiger M. Imaging of lung cancer with fluorine-18 fluorodeoxyglucose: comparison of a dual-head gamma camera in coincidence mode with a full-ring positron emission tomography system.  Eur J Nucl Med. 1999;  26 388-395